| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis; Arthritis, Rheumatoid | 詳細 |
| VDJ-001 | Phase 3 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Cardiovascular Diseases; Castleman Disease; Graves Ophthalmopathy; Multicentric Castleman's Disease (MCD); Renal Insufficiency, Chronic | 詳細 | |
| Tocilizumab Biosimilar (Curateq Biologics) | BP08; BP-08 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Arthritis, Rheumatoid | 詳細 |
| Tocilizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-087 | Phase 3 Clinical | Generium Pharmaceuticals | Arthritis, Rheumatoid | 詳細 |
| Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | 詳細 | |
| Tocilizumab biosimilar(Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| Levilimab | BCD-089 | Phase 3 Clinical | BIOCAD JSC | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Weizmann Institute Of Science | Diabetic Neuropathies; Peripheral Nervous System Diseases | 詳細 |
| Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 1 Clinical | Conaris Research Institute | Colitis, Ulcerative; Gastrointestinal Diseases | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tocilizumab | MRA-SC; R-1569; rhPM-1; RO-48775533; MRA; RG-1569; HPM-1 | Approved | Chugai Pharmaceutical Co Ltd | Actemra, Acterma, ACTPen, RoActemra, 雅美罗 | Japan | Arthritis, Rheumatoid | Chugai Pharmaceutical Co Ltd | 2005-04-11 | Acute Chest Syndrome; Amyotrophic Lateral Sclerosis; Anemia, Sickle Cell; Arthritis, Juvenile; Arthritis, Rheumatoid; Ascites; Behcet Syndrome; Breast Neoplasms; Carcinoma, Hepatocellular; Chondrocalcinosis; Coronary Artery Disease; Coronary Disease; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Craniopharyngioma; Cytokine Release Syndrome; Depressive Disorder, Major; Dermatomyositis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Fever; Giant Cell Arteritis; Graft vs Host Disease; Graves Ophthalmopathy; Hematologic Neoplasms; HIV Infections; Inflammation; Ischemic Stroke; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Lymphoma; Motor Neuron Disease; Myocardial Infarction; Neoplasms; Non-radiographic axial spondyloarthritis; Non-ST Elevated Myocardial Infarction; Osteoarthritis; Pancreatitis, Chronic; Panuveitis; Pleural Effusion, Malignant; Pneumonia; Polyarticular Juvenile Idiopathic Arthritis; Polymyalgia Rheumatica; Polymyositis; Pulmonary Arterial Hypertension; Pulmonary Disease, | 詳細 |
| Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis | 詳細 |
| Sarilumab | SAR-153191; REGN-88 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Polyarticular Juvenile Idiopathic Arthritis; Polymyalgia Rheumatica; Sarcoidosis; Severe Acute Respiratory Syndrome; Spondylitis, Ankylosing; Uveitis | 詳細 |
| Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | 詳細 |
| Tocilizumab biosimilar (Fresenius kabi) | MSB-11456; AT-220 (Arecor Therapeutics) | Approved | Merck Serono | Tyenne | EU | Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Arthritis, Rheumatoid; Brain Ischemia; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Subarachnoid Hemorrhage | 詳細 |
| Tocilizumab biosimilar (BioRay Pharm) | Approved | Hisun Biopharmaceutical Co Ltd | Mainland China | Arthritis, Rheumatoid | Hisun Biopharmaceutical Co Ltd | 2024-06-25 | Arthritis, Rheumatoid | 詳細 | ||
| Tocilizumab biosimilar (Celltrion) | CT-P47; CT-P-47 | Approved | Celltrion Inc | Avtozma | United States | Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile; Arthritis, Rheumatoid | Celltrion Inc | 2025-01-24 | Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis | 詳細 |
| Tocilizumab biosimilar (Maibo Taike) | CMAB-806; CMAB806 | Approved | Jinyu Bowo Runze Biotechnology Co Ltd, Taizhou Maibo Taike Biotechnology Co Ltd | Mainland China | Arthritis, Rheumatoid | Jinyu Bowo Runze Biotechnology Co Ltd | 2024-10-16 | Arthritis; Arthritis, Rheumatoid | 詳細 |